-
Arctic Vision and Santen Ink Deal for ARVN001 Commercialization in China
•
China-based ophthalmology specialist, Arctic Vision, has entered into a strategic collaboration with Japan’s Santen Pharmaceutical (TYO: 4536) for the commercialization of ARVN001, an innovative triamcinolone acetonide suprachoroidal injectable suspension. This partnership marks a significant step in the expansion of ophthalmic treatments, with Santen securing exclusive commercialization rights in mainland China…
-
Cloudbreak Pharma Partners with Santen Pharmaceutical for CBT-001 Commercialization in Southeast Asia
•
Cloudbreak Pharma Inc., a U.S.-based biopharmaceutical company, has entered into a strategic partnership with Japanese pharmaceutical firm Santen Pharmaceutical. The collaboration focuses on the development, manufacturing, and commercialization of Cloudbreak’s investigational drug, CBT-001, across Southeast Asia, including key markets such as Japan, Korea, Vietnam, Thailand, Malaysia, the Philippines, Singapore, and…
